VacV Biotherapeutics

VacV is a cancer immunotherapy company developing novel oncolytic viruses as cancer treatments. VacV was spun out from Barts Cancer Institute, one of the leading cancer research centers in the UK, following more than 20 years of pioneering research by Professor Yaohe Wang, a pioneer in cancer immunotherapy, and his team. The company has built a robust pipeline of cancer therapies based on oncolytic vaccinia viruses, which can both destroy cancer and generate a powerful anti-cancer immune response to eliminate disease and prevent future recurrence. VacV’s technology has been meticulously developed to offer significant advantages over existing immunotherapies, including minimal toxicity, high tumor specificity, effective and long-lasting anti-tumor efficacy, and systemic administration.